unknown
ARIEL4: An International, Multicenter, Randomized Phase 3 Study of the PARP Inhibitor Rucaparib vs Chemotherapy in Germline or Somatic BRCA1- or BRCA2-Mutated, Relapsed, High-Grade Ovarian Carcinoma
- Publication date
- 20 May 2017
- Publisher
- 'American Society of Clinical Oncology (ASCO)'